Cristcot

Executive Summary

Cristcot is a private pharmaceutical company specializing in innovative drug formulations and unobtrusive drug-device combination technologies, with a primary focus on gastroenterology. Its lead program for ulcerative colitis has successfully completed Phase 3 trials, positioning the company for regulatory filing. Cristcot aims to improve patient care by addressing critical obstacles in disease management, leveraging its proprietary platform to develop differentiated therapies. The company's early-stage pipeline and technology platform suggest potential for expansion into other gastrointestinal indications, though details remain undisclosed given its private status. With a seasoned management team and a focus on patient-centric solutions, Cristcot is poised for near-term value inflection as it advances toward commercialization.

Upcoming Catalysts (preview)

• Q2 2026NDA Submission for Ulcerative Colitis Drug80% success
• Q3 2026FDA Acceptance of NDA Filing75% success
• Q4 2026Series C or Later-Stage Financing Round60% success